We are Sorry, This Page doesn't Exist
Biogen, Gingko Bioworks enter gene therapy collaboration, license agreement
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Biogen price target raised to $325 from $300 at Oppenheimer
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Biogen"s Retinal Disease Gene Therapy Flunks Mid-Stage Study
Biogen Inc (NASDAQ: BIIB) has announced topline results from the Phase 2/3 XIRIUS study evaluating cotoretigene toliparvovec (BIIB112), a gene therapy being investigated as a one-time therapy for patients w.....»»
Biogen announces XIRIUS study results, did not meet primary endpoint
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Biogen"s Retinal Disease Gene Therapy Flunks Mid-Stage Study
read more.....»»
Biogen, Envisagenics announce RNA advancement collaboration
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Biogen exercises option to acquire TMS-007 from TMS
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Biogen, Capsigen announce collaboration on AAV capsids
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Unusual Options Activity Insight: Biogen
On Monday, shares of Biogen (NASDAQ:BIIB) saw unusual options activity. After the option alert, the stock price moved up to $275.74. read more.....»»
Denali-Biogen Parkinson"s Disease Candidate Shows Reductions In Biomarkers; Late Study To Begin By 2021 End
read more.....»»
Biogen Stock Is Estimated To Be Modestly Undervalued
Related Stocks: BIIB,.....»»
Biogen receives CRL from FDA for Tysabri SC route sBLA
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Biogen releases 2020 Year in Review outlining leadership actions over the year
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Biogen CEO nets highest-ever pay for second year in a row
For the second year in a row, Biogen CEO Michel Vounatsos has nabbed his highest-ever compensation, earning a grand total of $18.7 million......»»
Biogen says regulatory filings for aducanumab submitted in additional markets
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Biogen sees using part of remaining $4B buyback authorization throughout 2021
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Biogen raises FY21 adjusted EPS view to $17.50-$19.00 from $17.00-$18.50
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Biogen reports Q1 adjusted EPS $5.34, consensus $5.04
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Recap: Biogen Q1 Earnings
Shares of Biogen (NASDAQ:BIIB) moved higher by 1.4% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 41.58% year over year to $5.34, which beat the estimate of $5.04. read more.....»»
Biogen"s stock is up, though revenue fell 25% for the quarter
Shares of Biogen gained 1.4% in prem.....»»